Perspective Therapeutics (CATX) Operating Margin Growth (5y) (2015 - 2023)
Powered by 
Analysis
Perspective Therapeutics (CATX) Operating Margin Growth (5y) (2015 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 31,324.00 |
| Sep 30, 2023 | -34,904.00 |
| Jun 30, 2023 | -31,930.00 |
| Mar 31, 2023 | -38,802.00 |
| Sep 30, 2022 | 2,033.00 |
| Jun 30, 2022 | 7,176.00 |
| Mar 31, 2022 | 6,106.00 |
| Dec 31, 2021 | 8,581.00 |
| Sep 30, 2021 | 5,701.00 |
| Jun 30, 2021 | 7,163.00 |
| Mar 31, 2021 | 8,131.00 |
| Dec 31, 2020 | 8,158.00 |
| Sep 30, 2020 | 5,657.00 |
| Jun 30, 2020 | 3,021.00 |
| Mar 31, 2020 | 7,172.00 |
| Dec 31, 2019 | 5,482.00 |
| Sep 30, 2019 | 7,531.00 |
| Jun 30, 2019 | 7,959.00 |
| Mar 31, 2019 | 2,674.00 |
| Dec 31, 2018 | 2,117.00 |